 

West Pharmaceutical Services, Inc. reported strong first-quarter performance, with 13% organic sales growth and double-digit growth in adjusted earnings per share. The company's mission to improve patient lives has been further emphasized during the COVID-19 pandemic, as West has been focused on the well-being and safety of its team members and the continuity of manufacturing and supply of components and solutions to customers. The company's crisis management team has implemented precautionary measures to protect its teams, and its culture of philanthropy and community involvement has led to team members offering their time and skills to support local response efforts. West's full-year 2020 net sales guidance remains in a range of between $1.95 billion and $1.97 billion, with an estimated headwind of $26 million based on current foreign exchange rates. The company expects organic sales growth to be approximately 8%, and its full-year 2020 reported diluted earnings per share guidance to be in a range of $3.52 to $3.62.